Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
BUSINESS ASKA’s Birth Control Pill Makes Mark in Japan PIII Study
April 12, 2024
-
BUSINESS Moderna Plots Successive Launches in Japan, Updated COVID Jab by Fall: Medical Chief
April 11, 2024
-
REGULATORY Alexion’s Voydeya Marks 1st Application of “Early Launch Premium,” but Rate Fully Axed
April 11, 2024
-
REGULATORY Lagevrio to Get 8.2% Price Cut in July, 2.7% for Kerendia: CEA
April 11, 2024
-
REGULATORY Average PMP Rate Hits Record Low at 1.2% in FY2024: MHLW
April 11, 2024
-
BUSINESS GSK, Nagasaki University Begin Large-Scale Epidemiological Study on RSV
April 11, 2024
-
BUSINESS Teijin Out-Licenses Narcolepsy Drug to France’s Bioprojet
April 11, 2024
-
REGULATORY Nobelpharma, Argenx Challenged Initial Pricing for New Meds; Claims Partially Accepted
April 11, 2024
-
REGULATORY Argenx’s gMG Therapy Vyvdura OK’ed for Self-Injection
April 11, 2024
-
BUSINESS AZ/Fujifilm Develop Chemoradiotherapy Database for Lung Cancer
April 10, 2024
-
ORGANIZATION Only 3 Prefectures Log “Below 80%” Generic Rate in November: Kyokai Kenpo
April 10, 2024
-
REGULATORY Label Revision Ordered for 3 Beta Blockers to Delete Contraindication in Pregnant Women
April 10, 2024
-
BUSINESS Hypertension Therapy App Might Reduce Use of Antihypertensives: CureApp
April 10, 2024
-
REGULATORY Fanconi Syndrome Found in Majority of Health Damages Tied to Beni-Koji Supplements
April 10, 2024
-
BUSINESS Otsuka/Lundbeck Seek PTSD Nod for Rexulti in US
April 10, 2024
-
BUSINESS US FDA Grants Orphan Exclusivity for ALS Drug Radicava ORS
April 10, 2024
-
REGULATORY LDP Healthcare Clique Urges Rethink of Rationale for Off-Year Drug Price Revisions
April 10, 2024
-
BUSINESS R&D Jobs Make Up 40% of Pharma New Grads Hires This Spring, Sales Reps Only 20%: Poll
April 9, 2024
-
ORGANIZATION JPMA Launches Website Listing R&D Policies of Members to Help Foster Innovation Ecosystem
April 9, 2024
-
REGULATORY Lawmakers’ Group on Pollen Allergy to Compile Opinion Paper towards Honebuto
April 9, 2024
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…